Werewolf Therapeutics, Inc. (HOWL)

NMS – Real vaqt narxi. Valyuta: USD

0.63

-0.03 (-4.31%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.60

-0.03 (-5.06%)

Bozordan keyin: May 12, 2026, 7:38 PM EDT

07.05.2026

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the first quarter ended March 31, 2026.

27.03.2026

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value

24.02.2026

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that the Company will explore a full range of strategic alternatives to advance its promising platform and drug development pipeline to maximize stockholder value. The Company has engaged Piper Sandler & Co. (“Piper Sandler”) to serve as exclusive financial advisor to assist in the strategic evaluation process.

18.12.2025

Werewolf Therapeutics Announces Pipeline and Business Updates

WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI advanced or metastatic cutaneous melanoma patients, with potential best-in-class tolerability profile WTX-330 Phase 1b/2 trial initial data demonstrated additional evidence of antitumor activity and highly favorable tolerability profile, building upon monotherapy activity demonstrated in first-in-human Phase 1 clinical trial Additional Phase 1/1b data update for WTX-124 and completion of Part A of Phase 1b/2 clinical trial for WTX-330 are both expected in the first half of 2026 WTX-1011, Werewolf's first nominated INDUCER™ T cell engager development candidate targeting advanced, relapsed/refractory STEAP1-expressing cancers, continues to progress towards IND; with the announcement of Werewolf's second INDUCER development candidate, WTX-2022, targeting CDH6-expressing cancers, Werewolf is now planning for two INDs by mid-2027 WATERTOWN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced a pipeline update, including a review of recent data for its INDUKINE™ programs, and a business overview of its priorities for 2026 that includes a focus on the Company's highly differentiated INDUCER T cell engager platform.

15.12.2025

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

07.11.2025

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Novel INDUCER™ T Cell Engager Platform designed to mitigate systemic toxicities Sequential dosing of INDUKINE™ molecules in preclinical model showed potent antitumor activity with improved safety First-in-kind real-time pharmacokinetic data in a mouse tumor model confirmed WTX-124 selective activation in tumors, sparing healthy tissue WATERTOWN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today shared preclinical data at the 2025 Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, taking place November 5-9, 2025, in National Harbor, Maryland.

04.11.2025

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

– Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in the fourth quarter of 2025 – – Update on Phase 1b/2 clinical trial of WTX-330 and potential further development plan is expected to be provided later in the fourth quarter of 2025 – – WTX-1011, Company's first INDUCER™ T-cell engager development candidate targeting STEAP1, continues IND-enabling studies – WATERTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today provided a business update and reported financial results for the third quarter ended September 30, 2025.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

27.03.2026

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value

24.02.2026

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

18.12.2025

Werewolf Therapeutics, Inc. (HOWL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Search stocks

Werewolf Therapeutics, Inc. (HOWL)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates

Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

Werewolf Therapeutics Announces Pipeline and Business Updates